About PNH

Background image
Paroxysmal nocturnal haemoglobinuria (PNH) is a life-threatening rare stem cell condition in which a part of the immune system, called the complement system, attacks and destroys red blood cells inside blood vessels (known as intravascular haemolysis) and activate white blood cells and platelets which may cause blood clots (thromboses).1-4
Flask icon
Flask icon Flask icon Flask icon
It is not completely known why people develop PNH.1 Blood cells, including red blood cells, are made by stem cells in the bone marrow. PNH is caused by a fault, known as a mutation, in a specific gene called PIG-A (phosphatidylinositol glycan A) in one of the stem cells in the bone marrow.1,3-5 This mutation is acquired, which means that it is not inherited from a parent, and occurs randomly.3,6

The PIG-A gene is responsible for producing molecules called Glycosylphosphatidylinositol (GPI) anchors, which attach GPI-anchored proteins that protect the surface of blood cells from attack by complement. In people with PNH, the faulty or mutated PIG-A gene does not produce either enough or any of these GPI anchors so the protective proteins have nothing to attach to.1,3-5

Figure created by/for Alexion for illustrative purposes only

This results in the red blood cells being unprotected and liable to being attacked and destroyed by the complement system.1,3-5 This process is known as complement-mediated cell lysis or complement-mediated intravascular haemolysis.3

Haemolysis leads to a decrease in the number of red blood cells in the blood (anaemia), which is called intravascular haemolytic anaemia.1,5 In addition, white blood cells and platelets are activated by complement, which may cause blood clots (thromboses).1,5

The haemolysis that occurs in PNH takes place within blood vessels and is called intravascular haemolysis.7 Ongoing intravascular haemolysis in PNH can be destructive and the consequences may be life-threatening.8

The complement system is an important part of the immune system that protects the body against disease and infection.9

The complement system is usually in a ‘resting’ state – that means it is ready to act when needed. When it is working normally, a trigger for example, infection or surgery, causes the complement system to be activated in order to attack and remove any foreign or damaged cells.9

In PNH the complement system attacks blood cells, because they lack protective GPI-anchored proteins on the surface.2

Figure created by/for Alexion for illustrative purposes only

PNH has a diverse range of symptoms.9 The symptoms of PNH can change over time and vary from person to person. Some of the more common symptoms of PNH include1

Flask icon
Detecting PNH early makes managing and treating the condition easier and may lead to better outcomes. If you spot any of the symptoms above, speak to your doctor.
Szlendak U, Budziszewska B, Spychalska J, et al. Paroxysmal nocturnal hemoglobinuria: advances in the understanding of pathophysiology, diagnosis, and treatment. Pol Arch Intern Med 2022;132:16271.  Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804–2811. Risitano AM, Peffault de Latour R. How we(‘ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future. Br J Haematol 2022;196:288–303. Gembillo G, Siligato R, Cernaro V, et al. Complement inhibition therapy and dialytic strategies in paroxysmal nocturnal hemoglobinuria: the nephrologist’s opinion. J Clin Med 2020;9:1261. Brodsky RA. In: Hoffman R, et al., eds. Hematology: Basic Principles and Practice. Seventh edition. Elsevier; 2018:415–424; Jalbert JJ. Epidemiology of PNH and Real-World Treatment Patterns Following an Incident PNH Diagnosis in the US. Blood. 2019. Hill A, DeZern AE, Kinoshita T, et al. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers 2017;3:1702. Sahin F, Ozkan MC, Mete NG, et al. Multidisciplinary clinical management of paroxysmal nocturnal hemoglobinuria. Am J Blood Res. 2015;5(1):1–9. Walport M.J, New England Journal of Medicine 2001 1058–1066. Merle NS, et al. Complement system part I: molecular mechanisms of activation and regulation. Frontiers in Immunology 2015.